The aim of this study was to determine the cumulative probability of taking CsA in comparison to other DMARDs, as well as the reason for discontinuation of each DMARD, in a large cohort of PsA patients.
We prospectively studied 172 consecutive patients with a diagnosis of PsA who had been admitted to our rheumatological unit since 1984.
We collected information about treatment with DMARDs including : number, dose, duration and causes of withdrawal, including side effects or inefficacy.
Cumulative survival analysis was performed by the Kaplan-Meier test and the differences between these survival curves were detemined by the Mantel-Hanszel test.
The probability curve of continuing to take CsA was significantly lower than that of MIX (p<0.046).
The rate of adverse effects responsible for stopping DMARD therapy was higher in the CsA group, especially with respect to the antimalarial group (p<0.014).
The most common cause of CsA withdrawal was hypertension.
The rate of withdrawal due to inefficacy in the CsA group was not significantly different from those observed in the other groups.
Nevertheless, the total frequency of discontinuation due to toxicity and inefficacy in the MIX group was significantly lower compared to the gold salts (p<0.05) and CsA groups (p<0.01).
Life-table analysis suggests that PsA patients taking CsA are less likely than patients on MTX to continue long term treatment. (...)
Mots-clés Pascal : Rhumatisme psoriasique, Homme, Traitement, Ciclosporine, Chimiothérapie, Pronostic, Efficacité traitement, Long terme, Modalité traitement, Epidémiologie, Table mortalité, Psoriasis, Immunodépresseur, Peau pathologie, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire, Spondylarthropathie
Mots-clés Pascal anglais : Psoriatic arthritis, Human, Treatment, Ciclosporin, Chemotherapy, Prognosis, Treatment efficiency, Long term, Application method, Epidemiology, Life table, Psoriasis, Immunosuppressive agent, Skin disease, Diseases of the osteoarticular system, Inflammatory joint disease, Spondylarthropathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0047710
Code Inist : 002B02L. Création : 14/05/1998.